ischemic stroke

[Athersys, Inc.] Athersys, Inc. announced that its partner, HEALIOS K.K. provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.

[Journal of Clinical Investigation] The authors observed increased plasma and platelet surface expressed high mobility group box 1 in stroke patients. Mechanistically, platelets were identified as the critical source for HMGB1 causing neutrophil extracellular trap in the acute phase of stroke.

[Scientific Reports] With the aim of designing a preclinical study evaluating an intracerebral cell-based therapy for stroke, an observational study was performed in the rat suture model of ischemic stroke.

[Acticor Biotech] Acticor Biotech announced positive results from its ACTIMIS Phase Ib/IIa clinical trial using glenzocimab as an add-on to standard of care in patients with AIS.

[Histology and Histopathology] Investigators review the levels of S1P in those vascular and vascular-related diseases. Plasma S1P levels were reduced in various inflammation-related diseases such as atherosclerosis and sepsis, but were increased in other diseases including type 2 diabetes, neurodegeneration, and cerebrovascular damage.

[Current Stem Cell Research & Therapy] The authors explored the contribution of miRNAs in adipose-derived stem cell-extracellular vesicles to the treatment of cerebral ischemia.